The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Nonalcoholic fatty Liver disease: pathogenesis and treatment

비알코올성 지방간 질환

Yeon, Jong-Eun
연종은

  • Published : 20060300
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med;346:1221-1231, 2002 https://doi.org/10.1056/NEJMra011775
  2. Chitturi S, Farrell GC, George J. Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock? J Gastroenterol Hepatol 19:368-374, 2004 https://doi.org/10.1111/j.1440-1746.2003.03252.x
  3. Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, Faga E, Silli B, Pagano G. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 37:909-916, 2003 https://doi.org/10.1053/jhep.2003.50132
  4. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 122:1649-1657, 2002 https://doi.org/10.1053/gast.2002.33573
  5. Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, Wasada T. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 22:1141-1145, 2005 https://doi.org/10.1111/j.1464-5491.2005.01582.x
  6. Hilden M, Christoffersen P, Juhl E, Dalgaard JB. Liver histology in a 'normal' population--examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 12:593-597, 1977 https://doi.org/10.3109/00365527709181339
  7. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 35:367-372, 2002 https://doi.org/10.1053/jhep.2002.30690
  8. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37:1202-1219, 2003 https://doi.org/10.1053/jhep.2003.50193
  9. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121:91-100, 2001 https://doi.org/10.1053/gast.2001.25540
  10. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease:a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42:132-138, 2005
  11. Hui JM, Kench JG, Chitturi S, Sud A, Farrell GC, Byth K, Hall P, Khan M, George J. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 38:420-427, 2003
  12. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a populationbased cohort study. Gastroenterology 129:113-121, 2005 https://doi.org/10.1053/j.gastro.2005.04.014
  13. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36:1349-1354, 2002 https://doi.org/10.1002/hep.1840360609
  14. Fishbein MH, Gardner KG, Potter CJ, Schmalbrock P, Smith MA. Introduction of fast MR imaging in the assessment of hepatic steatosis. Magn Reson Imaging 15:287-293, 1997 https://doi.org/10.1016/S0730-725X(96)00224-X
  15. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123:745-750, 2002 https://doi.org/10.1053/gast.2002.35354
  16. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-1321, 2005 https://doi.org/10.1002/hep.20701
  17. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127: 1704-1713, 2004 https://doi.org/10.1053/j.gastro.2004.08.052
  18. Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, Bertet J, Couzigou P, de Ledinghen V. Diagnosis of cirrhosis by transient elastography (Fibroscan(R)): a prospective study. Gut, 2005
  19. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279:32345-32353, 2004 https://doi.org/10.1074/jbc.M313478200
  20. Kraegen EW, Clark PW, Jenkins AB, Daley EA, Chisholm DJ, Storlien LH. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 40:1397-1403, 1991 https://doi.org/10.2337/diabetes.40.11.1397
  21. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 307:384-387, 2005 https://doi.org/10.1126/science.1104343
  22. Diehl AM, Li ZP, Lin HZ, Yang SQ. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 54:303-306, 2005 https://doi.org/10.1136/gut.2003.024935
  23. Masaki T, Chiba S, Tatsukawa H, Yasuda T, Noguchi H, Seike M, Yoshimatsu H. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 40:177-184, 2004 https://doi.org/10.1002/hep.20282
  24. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114: 147-152, 2004 https://doi.org/10.1172/JCI200422422
  25. George J, Pera N, Phung N, Leclercq I, Yun Hou J, Farrell G. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol 39:756-764, 2003 https://doi.org/10.1016/S0168-8278(03)00376-3
  26. McCuskey RS, Ito Y, Robertson GR, McCuskey MK, Perry M, Farrell GC. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology 40:386-393, 2004 https://doi.org/10.1002/hep.20302
  27. Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, Powell EE. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 53:413-419, 2004 https://doi.org/10.1136/gut.2003.027581
  28. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB. Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholinduced steatohepatitis: a pilot study. Hepatology 23:1464-1467, 1996 https://doi.org/10.1002/hep.510230624
  29. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39:770-778, 2004 https://doi.org/10.1002/hep.20092
  30. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 31:384, 1999 https://doi.org/10.1016/S0168-8278(99)80243-8
  31. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 358:893-894, 2001 https://doi.org/10.1016/S0140-6736(01)06042-1
  32. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38: 1008-1017, 2003 https://doi.org/10.1002/hep.1840380427
  33. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang TJ, Yanovski JA, Kleiner DE, Hoofnagle JH. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39:188-196, 2004 https://doi.org/10.1002/hep.20012
  34. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 136:734-738, 2000 https://doi.org/10.1067/mpd.2000.106566
  35. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 96:2711-2717, 2001 https://doi.org/10.1111/j.1572-0241.2001.04129.x
  36. Harrison SA, Ramrakhiani S, Brunt EM, Anbari MA, Cortese C, Bacon BR. Orlistat in the treatment of NASH: a case series. Am J Gastroenterol 98:926-930, 2003 https://doi.org/10.1111/j.1572-0241.2003.07375.x
  37. Mun EC, Blackburn GL, Matthews JB. Current status of medical and surgical therapy for obesity. Gastroenterology 120:669-681, 2001 https://doi.org/10.1053/gast.2001.22430
  38. Limanond P, Raman SS, Lassman C, Sayre J, Ghobrial RM, Busuttil RW, Saab S, Lu DS. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology 230:276-280, 2004 https://doi.org/10.1148/radiol.2301021176
  39. Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J, Boparai N. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 7:797-801, 2001 https://doi.org/10.1053/jlts.2001.24644